Elevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death by Garcia-Carbonell, Ricard et al.
Elevated A20 promotes TNF-induced and RIPK1-
dependent intestinal epithelial cell death
Ricard Garcia-Carbonella,b,c,d,1, Jerry Wonga,b,c,1, Ju Youn Kima,b,c, Lisa Abernathy Closee, Brigid S. Bolandf,
Thomas L. Wonga,b,c, Philip A. Harrisg, Samuel B. Hoh, Soumita Dasc, Peter B. Ernstc, Roman Sasiki,j, William J. Sandbornf,
John Berting, Pete J. Goughg, John T. Changf, Michelle Kelliherk, David Boonee, Monica Gumaa,b,c,l,m,2,
and Michael Karina,b,c,2
aLaboratory of Gene Regulation and Signal Transduction, University of California, San Diego, CA 92093; bDepartment of Pharmacology, University of
California, San Diego, CA 92093; cDepartment of Pathology, University of California, San Diego, CA 92093; dDepartment of Biochemistry and Molecular
Biology, Faculty of Pharmacy, University of Barcelona, Barcelona, Spain; eDepartment of Microbiology and Immunology, Indiana University School of
Medicine, South Bend, IN 46617; fDepartment of Medicine, Division of Gastroenterology, University of California, San Diego, CA 92093; gPattern
Recognition Receptor Discovery Performance Unit, Immuno-Inflammation Therapeutic Area, GlaxoSmithKline, Collegeville, PA 19426; hDepartment of
Medicine, VA San Diego Healthcare System, San Diego, CA 92161; iCenter for Computational Biology, University of California, San Diego, CA 92093;
jInstitute for Genomic Medicine, University of California, San Diego, CA 92093; kDepartment of Molecular, Cell and Cancer Biology, University of
Massachusetts Medical School, Worcester, MA 01605; lDepartment of Medicine, Division of Rheumatology, University of California, San Diego, CA 92093;
and mDepartment of Medicine, Autonomous University of Barcelona, 08193 Bellaterra, Barcelona, Spain
Contributed by Michael Karin, August 14, 2018 (sent for review June 20, 2018; reviewed by Anning Lin and Zheng-Gang Liu)
Intestinal epithelial cell (IEC) death is a common feature of
inflammatory bowel disease (IBD) that triggers inflammation by
compromising barrier integrity. In many patients with IBD, epithe-
lial damage and inflammation are TNF-dependent. Elevated TNF
production in IBD is accompanied by increased expression of the
TNFAIP3 gene, which encodes A20, a negative feedback regulator
of NF-κB. A20 in intestinal epithelium from patients with IBD co-
incided with the presence of cleaved caspase-3, and A20 trans-
genic (Tg) mice, in which A20 is expressed from an IEC-specific
promoter, were highly susceptible to TNF-induced IEC death, in-
testinal damage, and shock. A20-expressing intestinal organoids
were also susceptible to TNF-induced death, demonstrating that
enhanced TNF-induced apoptosis was a cell-autonomous property
of A20. This effect was dependent on Receptor Interacting Protein
Kinase 1 (RIPK1) activity, and A20 was found to associate with the
Ripoptosome complex, potentiating its ability to activate caspase-
8. A20-potentiated RIPK1-dependent apoptosis did not require the
A20 deubiquitinase (DUB) domain and zinc finger 4 (ZnF4), which
mediate NF-κB inhibition in fibroblasts, but was strictly dependent
on ZnF7 and A20 dimerization. We suggest that A20 dimers bind
linear ubiquitin to stabilize the Ripoptosome and potentiate its
apoptosis-inducing activity.
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Crohn’s disease (CD) and ulcerative colitis (UC) are commonIBDs characterized by intestinal epithelial injury, including
mucosal erosion, ulceration, cryptitis, and crypt abscess forma-
tion (1). In many patients with IBD, epithelial damage and in-
flammation depend on TNF, and in most such patients, anti-
TNF drugs prevent intestinal epithelial cell (IEC) death and
promote healing and mucosal regeneration, at least temporarily
(2). Normally, IECs resist TNF-induced death due to activation
of NF-κB (3–5), which, in addition to anti-apoptotic genes (6),
controls transcription of genes that maintain barrier integrity and
microbial homeostasis (7). Hence, the mechanisms that convert
TNF to a potent inducer of IEC death and tissue injury in a large
fraction of patients with IBD are of importance but remain ob-
scure. Looking for genes that are coregulated with TNF, we
found a strong correlation between TNF and TNFAIP3 mRNA
expression in several different IBD patient cohorts. TNFAIP3,
which codes for the putative antiinflammatory protein A20,
contains three intronic single-nucleotide polymorphisms (SNPs)
associated with responsiveness to anti-TNF drugs, such that
lower A20 expression correlates with improved drug response
(8). Curiously, however, mice with enterocyte-specific A20
deletion are hypersensitive to dextran sodium sulfate (DSS)-
induced colitis and TNF-induced epithelial apoptosis (9), ef-
fects that are inconsistent with the known ability of A20 to sup-
press activation of NF-κB (10), which promotes IEC survival (7).
Another puzzling finding is induction of early-onset colitis by
transgenic (Tg) A20 in IL-10–deficient mice (11). The same
A20 Tg mice, however, are protected from DSS-induced, but
not 2,4,6-trinitrobenzenesulfonic acid-induced, colitis (12).
A20 contains an N-terminal ovarian tumor (OTU) deubiqui-
tinase (DUB) domain and seven C-terminal ZnF motifs that
have been assigned distinct functions, including Lys63 (K63)-
linked polyubiquitin binding by ZnF4 and Met1(M1)-linked lin-
ear ubiquitin binding by ZnF7 (13). ZnF1 was reported to bind the
protein kinase RIPK1, whereas ZnF4 harbors E3 ubiquitin ligase
activity (14). Upon TNF receptor 1 (TNFR1) engagement,
TNFR1 itself and RIPK1 are modified by the linear and K63-
linked ubiquitin ligases cIAP1 and cIAP2, which facilitate
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RIPK1 recruitment to TNFR1 and generate a signaling complex
that promotes IκB kinase (IKK)-mediated NF-κB activation (15).
By removing K63-linked polyubiquitin, the A20 DUB domain
was proposed to prevent RIPK1 interaction with the IKK reg-
ulatory subunit IKKγ/NEMO, and by adding K48-linked poly-
ubiquitin, in a ZnF4-dependent manner, A20 was suggested to
induce RIPK1 degradation (14). However, mice expressing a
ZnF4-deficient A20 variant do not exhibit the same phenotype
as Tnfaip3-null mice (13, 16), questioning the importance of the
E3 ligase activity embedded within ZnF4. Furthermore, a DUB-
defective Tnfaip3 allele does not cause multiorgan inflammation,
and fibroblasts homozygous for the DUB deficiency do not show
marked differences in TNF-induced NF-κB activation (13, 16,
17). Obviously, not all A20 activities are NF-κB–directed, and its
likely involvement and mode of action in IBD pathogenesis
merit further investigation.
Results
A20 and Caspase-3 Activation in Human IBD. We examined A20
expression in IBD specimens by comparing ileal and colonic CD
transcriptomes with those of healthy tissue. The results revealed
strong up-regulation of TNF mRNA and other NF-κB target
genes, including TNFAIP3 (Fig. 1A and SI Appendix, Fig. S1A),
which was also up-regulated in UC (SI Appendix, Fig. S1A).
Mining of publicly available IBD datasets revealed a strong
positive correlation between TNFAIP3, TNF, and BIRC3 tran-
scripts (SI Appendix, Fig. S1B), suggesting that A20 may not
inhibit NF-κB–mediated transcription in IBD tissues. Further-
more, most patients with high TNF mRNA also showed high
TNFAIP3 mRNA (SI Appendix, Fig. S1C). Immunohistochemi-
cal (IHC) analysis revealed that A20 was up-regulated in both
lamina propria cells and IECs of active IBD tissue and that
its expression in IECs correlated with that of cleaved caspase-3
(cC-3; P < 0.0001, r = 0.73; n = 23 samples), which marks apo-
ptotic cells (Fig. 1B and SI Appendix, Fig. S2 and Table S1). The
level of inflammation reported for these samples showed a
modest correlation with A20 (P < 0.0085, r = 0.49; n = 23 sam-
ples) and cC-3 (P = 0.05, r = 0.4; n = 23 samples) expression (SI
Appendix, Fig. S3), further confirming A20 up-regulation and
apoptosis in inflamed IBD tissues.
TNF-Induced Apoptosis in A20 Tg Mice. A20 expression in IECs was
reported to either restrain apoptosis and maintain barrier func-
tion (9, 18) or promote development of colitis (11), two dia-
metrically opposed outcomes, neither of which is fully consistent
with A20-mediated inhibition of NF-κB signaling. To determine
how elevated A20 affects the viability of TNF-exposed IECs, we
used villin-Tnfaip3 (hereafter A20) Tg mice (18). These mice are
healthy and display normal growth and intestinal development
(12), but after i.v. injection of 1 μg of murine TNF, all A20 Tg
mice died within 6 h, whereas all C57BL/6 (hereafter B6) control
mice survived (SI Appendix, Fig. S4 A and B). TNF-challenged
A20 Tg mice exhibited a markedly elevated septic score and a
dramatic drop in body temperature (SI Appendix, Fig. S4B).
TNF-challenged A20 Tg mice showed enhanced IL-6 production
with a mild increase in lung inflammatory infiltrates and splenic
architecture disruption but no obvious damage to the kidneys or
liver (SI Appendix, Fig. S4 D and E). TNF challenge resulted in
extensive mucosal erosion, with complete loss of villi in the small
bowel, and caspase-3 activation in the small intestine and large
intestine of A20 Tg mice (Fig. 1 C and D).
TNF-Induced Apoptosis in A20-Expressing Enteroids. A20 Tg mice
that are IL-10–deficient exhibit defective expression of mucosal
cytokines and antimicrobial peptides, resulting in microbial col-
onization of the inner mucus layer, along with microbial dysbiosis
(11). To assess IEC-autonomous A20 effects, we used enteroid
(intestinal organoid) cultures, which retain normal epithelial
differentiation and are free of microbes and immune cells (19).
Whereas B6 enteroids remained intact, A20 Tg enteroids un-
derwent extensive TNF-induced cell death, especially within
villus domains (Fig. 2 A and B). Four hours after TNF challenge,
immunofluorescence analysis revealed cC-3 in A20 Tg enteroid
villus domains (Fig. 2B), consistent with TNF-induced villus
erosion in vivo (Fig. 1D). A20 Tg enteroids also showed strong
cC-3/cC-8 expression by immunoblotting (IB), whereas control
enteroids were unaffected (Fig. 2C), indicating that immune cells
and gut microbiota are not needed for TNF-induced apoptosis of
A20-expressing IECs. We validated these findings by transducing
control enteroids with a doxycycline (DOX)-inducible A20
(iA20) construct. A20 induction strongly potentiated TNF-
induced caspase activation (Fig. 2D), indicating that the results
are not due to any reprogramming that is peculiar to A20 Tg mice.
A20 Has a Minor Effect on NF-κB Activation and Transcriptional
Activity in IECs. As found in human IBD specimens, elevated
A20 did not reduce mRNA and protein expression of anti-
apoptotic genes and NF-κB–related molecules in the small in-
testine and large intestine of A20 Tg mice (Fig. 3 A and B). A20
Tg and DOX-treated iA20 enteroids also did not show any de-
fect in expression of antiapoptotic genes and NF-κB–related
molecules (Fig. 3C). TNF-induced IκBα degradation was slightly
decreased in A20-expressing enteroids (Fig. 3D). Likewise, IKK
activation was partially blunted in A20 Tg organoids (Fig. 3E),
but iA20 expression had a miniscule effect on IKK activation
(Fig. 3F and SI Appendix, Fig. S8 B and C), although it fully
potentiated TNF-induced cell death (Fig. 2D). Moreover, al-
though expression of some NF-κB target genes was reduced at
baseline in A20 Tg enteroids, their TNF-induced expression was
marginally affected by DOX-induced iA20 (SI Appendix, Fig. S5
A and B). These results are generally consistent with lower
A20 levels in iA20 enteroids relative to Tg A20 (Fig. 3C) and
suggest that TNF-induced apoptosis in A20-expressing cells was
not secondary to NF-κB inhibition and decreased antiapoptotic
gene expression. Thus, unlike its effect in other cell types (20),
A20 has only a minor effect on NF-κB signaling in IECs.
RIPK1 Activity Is Required for A20-Potentiated TNF-Induced Apo-
ptosis. TNF-induced cell death depends on formation of death-
inducing signaling complexes. Whereas complex IIa mediates
classical apoptosis when synthesis of antiapoptotic proteins is
inhibited, complex IIb, also known as the Ripoptosome be-
cause of its dependence on RIPK1 activity, mediates apoptosis
in cells treated with second mitochondria-derived activator of
caspase (SMAC) mimetics that induce cIAP1/2 degradation
(15). By contrast, complex III, whose activity depends on both
RIPK1 and RIPK3, mediates programmed necrosis when cas-
pase activity is blocked (21). We used pharmacological inhibitors
of RIPK1 [Necrostain-1 (Nec-1), Nec-1s, and GSK′963] and
RIPK3 (GSK′843 and GSK′872) (22–24) to discern the in-
volvement of RIPK1 and RIPK3 in TNF-induced death of A20-
expressing IECs. Whereas RIPK1 inhibitors prevented TNF-
induced cell death and caspase activation, RIPK3 inhibitors
did not (Fig. 4 A and B). Similar results were obtained in
iA20 enteroids (Fig. 4C). However, iA20 expression in enteroids
derived from Ripk1 kinase dead knock-in mice (Ripk1KDKI) (25)
did not sensitize the cells to TNF-induced apoptosis (Fig. 4D).
Furthermore, administration of the RIPK1 inhibitor GSK′963 by
i.p. injection to A20 Tg mice 1 h before TNF challenge greatly
improved the septic score and inhibited mucosal erosion (Fig. 4
E and F). Of note, the RIPK1 inhibitor did not block cytokine
and inflammatory gene induction on TNF challenge (SI Ap-
pendix, Fig. S6).
A Critical Role for ZnF7 in TNF-Induced RIPK1-Dependent IEC Death.
RIPK1 activation and its proapoptotic activity are triggered upon
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its incorporation into the Ripoptosome, which also contains C8,
cFLIP, and FADD (15, 26–28). FADD immune complexes from
TNF (T)-stimulated A20-expressing enteroids that were briefly
treated with Z-VAD-FMK (Z) to retain active C8 within the
Ripoptosome (15) contained much more cC-8 than FADD
complexes from T + Z-incubated B6 enteroids (Fig. 5A). Im-
portantly, A20 was also present in FADD immune complexes
from T + Z-stimulated A20-expressing enteroids (Fig. 5A),
A B
C D
Fig. 1. Increased TNFAIP3 (A20) expression in human IBD specimens and mice correlates with IEC apoptosis. (A) Heat maps of IBD-related genes that are
differentially expressed between ileal (n = 3) and colonic (n = 3) CD and healthy tissue. (B) IHC double staining of cC-3 (black) and A20 (red) in control and UC
colonic sections. (Scale bars: Left, 50 μm; Right, 10 μm.) Representative H&E and cC-3 IHC staining of jejunal and colonic sections from B6 and A20 Tg mice at
time 0 (C) and 4 h after TNF injection (D) is shown (1 μg administered i.v., n = 5). (Scale bars: 100 μm.)
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suggesting that A20 enhances Ripoptosome formation by inter-
acting with one of its components. Of note, B6 enteroids treated
with cycloheximide (CHX) and incubated with T + Z, a combi-
nation that triggers TNF-induced cell death independent of
RIPK1 activation (SI Appendix, Fig. S7A), exhibit minimal C8 or
A20 recruitment to FADD (Fig. 5A). As expected, addition of Nec-
1 to inhibit RIPK1 prevented the appearance of cC-8 in the FADD
immune complexes. Expression of cIAP1, whose degradation
promotes Ripoptosome formation (15), was similar in B6- and
A20-expressing IECs and enteroids (Fig. 3 B and C), indicating
that A20 does not operate by suppressing cIAP1 expression.
RIPK1 is modified by K63-linked polyubiquitin (13), whose
removal by CYLD facilitates Ripoptosome formation (15). As
A20 can also remove K63-linked polyubiquitin from RIPK1 (14),
we examined the ubiquitination status of TNFR1-associated
RIPK1, expecting to find less ubiquitinated RIPK1 in A20 Tg
enteroids. Much to our surprise, A20 expression attenuated the
deubiquitination of TNFR1-bound RIPK1, which was almost
complete in B6 enteroids at 60 min after TNF addition (Fig. 5B).
Furthermore, A20 expression increased the amount of TNFR1-
bound RIPK1. In contrast, CHX pretreatment had no effect on
deubiquitination of TNFR1-bound RIPK1 (SI Appendix, Fig.
S7B), further demonstrating that the mechanism that promotes
TNF-induced cell death after NF-κB inhibition (by CHX) is
distinct from the one that accounts for A20-enhanced Ripopto-
some formation. As reported (13), A20 itself was incorporated
into the TNFR1 signaling complex (Fig. 5B). Of note, CYLD
protein expression was similar in B6- and A20-expressing IECs
and enteroids (Fig. 3C).
We conducted mutational analysis to identify A20 functional
domains required for enhancement of TNF-mediated caspase
activation. Inducible A20 variants lacking either DUB activity
due to a C103A OTU domain substitution (14) or K48-linked
E3 ligase function (C609A/C612A), which resides in ZnF4 (13),
were as effective as WT iA20 in sensitizing IECs to TNF-induced
apoptosis (SI Appendix, Fig. S8A). Next, we examined the role of
ZnF7, which is required for binding of linear polyubiquitin (29),
using a C764A/C767A double-substitution mutant. Notably, ex-
pression of the ZnF7 mutant failed to enhance TNF-induced
caspase activation, whereas the OTU-deficient mutant was
fully functional (Fig. 5C). Of note, the different A20 mutations
had minor effects on inhibition of IKK activation, which was
barely noted even for WT iA20 (SI Appendix, Fig. S8). Most
importantly, the ZnF7 mutant was not recruited to FADD and
was compromised in enhancement of Ripoptosome formation/
C8 activation (Fig. 5D).
A Critical Role for A20 Homodimerization in TNF-Induced RIPK1-
Dependent IEC Death. A20 forms homodimers through a dimer-
ization surface within its N-terminal portion (16). We generated
a homodimerization-restricted (HR) iA20 variant containing
M15A, R16E, and H351A substitutions (16). The iA20HR var-
iant failed to potentiate TNF-induced cell death (Fig. 6A), al-
though it was efficiently expressed and as capable of modest
IKK/NF-κB inhibition as WT A20 (Fig. 6 B and C). Of note,
iA20HR was compromised in its association with FADD com-
plexes and failed to potentiate C8 activation/Ripoptosome for-
mation (Fig. 6D and SI Appendix, Fig. S9). Collectively, these
results suggest that A20 facilitates Ripoptosome assembly by
binding as a dimer to linear ubiquitin chains via ZnF7, thereby
protecting RIPK1 from deubiquitination, stabilizing the Ripop-
tosome complex, and enhancing caspase-8 recruitment and ac-
tivation (Fig. 7).
Discussion
Genome-wide association studies identified TNFAIP3 as a dis-
ease susceptibility locus in several inflammatory diseases, in-
cluding IBD (29). However, most disease-associated SNPs within
the TNFAIP3 locus are located in noncoding regions, and their
effects on A20 expression and IBD pathogenesis are unknown
(29). Furthermore, SNPs that reduce A20 expression are asso-
ciated with improved response to anti-TNF drugs (8). None-
theless, it is unknown within what types of cells A20 acts to
influence IBD pathogenesis. We found that A20 is highly
expressed in the mucosa of patients with IBD and that its ele-
vated expression in IECs is associated with caspase-3 activation,
likely causing barrier deterioration and intestinal inflammation.
Using Tg mice expressing A20 in IECs (18), we found that ele-
vated A20 greatly enhances susceptibility to TNF-induced apo-
ptosis, resulting in barrier deterioration and acute inflammation.
These findings challenge the view that A20 is predominantly an
antiinflammatory protein, which is based on the ability of
A20 ablation to cause severe inflammation through TNF-
dependent and -independent pathways (13, 14, 30). Of all dif-
ferent forms of TNF-induced cell death, A20 specifically po-
tentiates RIPK1-dependent apoptosis (also known as ripoptosis),
a phenomenon originally identified in cultured cells treated with
SMAC mimetics (15), but heretofore not shown to occur in vivo.
In some cells, A20 functions as a feedback inhibitor of NF-κB
(10, 20), an activity that depends on removal of K63-linked
polyubiquitin chains from RIPK1 via A20 DUB activity and
addition of K48-linked polyubiquitin via A20 ZnF4 (13, 14).
However, in vivo studies have failed to reveal a major effect of
A20 on NF-κB (16, 17), although inactivation of its OTU/DUB
domain or ZnF4 enhanced both p38 and JNK activation (13).
Furthermore, in IECs, A20 had little effect on NF-κB signaling
and actually slowed down deubiquitination of TNFR1-bound
RIPK1. In addition, recent work showed that A20’s functions
depend on interactions with other proteins (13, 31, 32). It is
therefore plausible that the availability of these secondary me-
diators as well as the stoichiometry of complexes that form
downstream of the TNF receptor may vary depending on the cell
type, which would explain an enhanced cell death instead of
Fig. 2. Elevated A20 sensitizes enteroids to TNF-induced apoptosis. (A)
Bright-field images of B6 and A20 Tg enteroids at time 0 and 4 h after TNF
(40 ng/mL) addition. (Magnification: 200×.) (B) Confocal images of cC-3–
stained enteroids after TNF addition as in A. (Scale bars: 50 μm.) (C) IB of
B6 and A20 Tg enteroids with or without TNF (40 ng/mL) stimulation. (D) IB
of iA20 enteroids incubated with or without DOX (1 μg/mL for 24 h) before
TNF addition. mTNF, mouse TNF; NS, nonspecific band.
Garcia-Carbonell et al. PNAS | vol. 115 | no. 39 | E9195
M
ED
IC
A
L
SC
IE
N
CE
S
complete NF-κB pathway blockade. Indeed, A20 itself is
recruited into the Ripoptosome complex in a manner dependent
on its ZnF7, which exhibits high affinity to linear ubiquitin chains
(13). Neither the OTU/DUB domain nor ZnF4 is involved in
Ripoptosome recruitment and activation. Given the dependence
of Ripoptosome recruitment on ZnF7, it is plausible that
A B
C D
E F
Fig. 3. Elevated A20 has a minimal effect on NF-κB signaling in IECs and enteroids. (A) Real-time qPCR analysis of the indicated transcripts in jejunal and
colonic IECs from B6 and A20 Tg mice. Results are mean ± SEM. (B) IB analysis of jejunal and colonic lysates from B6 and A20 Tg mice. (C) IB analysis of lysates
of untreated and DOX-treated B6, A20Tg, and iA20-transduced enteroids. (D) IB analysis of indicated proteins in lysates of B6, A20Tg, and DOX-treated
iA20 enteroids stimulated with TNF. (E and F) IKK activity was assessed by immune complex kinase assay using GST-IκBα(1–54) as a substrate in lysates of the
indicated enteroids (the images in F are taken from the blot shown in SI Appendix, Fig. S8B).
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A20 may bind to the linear ubiquitin chains attached to K115 of
RIPK1 (33–35). By binding linear ubiquitin chains, A20 can in-
hibit their degradation or removal (36, 37). Notably, inactivation
of HOIP, the ubiquitin ligase subunit of the linear ubiquitination
assembly complex (LUBAC), prevents A20 recruitment to the
TNFR1 signaling complex (36), a finding consistent with our
suggestion that A20 binds RIPK1 once the latter has been sub-
ject to LUBAC-mediated linear ubiquitination.
A20-enhanced, TNF-induced Ripoptosome formation is pre-
vented by ZnF7 inactivation or restriction of A20 homodimeri-
zation. These findings suggest that A20 binds to RIPK1 linear
ubiquitin chains as a dimer, thereby stabilizing the Ripoptosome
and potentiating activation of its caspase-8 moiety via induced
proximity (Fig. 7). A similar model was proposed to explain
TRAIL-induced caspase-8 activation. Although, by themselves,
caspase-8 dimers are unstable and may fall apart once released
from the death-inducing signaling complex (DISC) (38, 39), the
binding of p62/SQSTM1 to caspase-8–linked K63 polyubiquitin
chains enhanced caspase-8 oligomerization and activation (40).
Much of the biochemical information gathered about A20 and
its participation in TNF signaling was obtained using fibroblasts,
in which A20 restricts NF-κB signaling. Although A20 weakly
attenuates NF-κB activation in IECs, it does not inhibit expres-
sion of NF-κB–dependent antiapoptotic genes. Furthermore,
while NF-κB inhibition was reported to depend on the A20 DUB
and ZnF4 motifs (13), neither of these motifs affects RIPK1
activation and TNF-induced cell death. Thus, the ability of
A20 to enhance TNF-induced apoptosis is not due to NF-κB
inhibition, which facilitates complex IIA-dependent apoptosis
(21). We propose that elevated A20 expression is an important
contributor to barrier disruption and initiation of microbiota-
dependent inflammation in patients with IBD who produce
higher than normal amounts of TNF. Of note, the complete
absence of A20 is not healthy either, as it also increases the
Fig. 4. TNF-induced apoptosis of A20-expressing IECs depends on RIPK1 kinase activity. (A) Bright-field images of A20 Tg enteroids incubated with TNF for
4 h without or with RIPK1 or RIPK3 inhibitors. mTNF, mouse TNF. (Magnification: 200×.) (B) IB analysis of B6 and A20 Tg enteroids treated as above. (C) IB
analysis of iA20-transduced B6 enteroids after 24-h DOX pretreatment and TNF stimulation for 5 h without or with RIPK1 or RIPK3 inhibitors. (D) IB analysis of
iA20-transduced B6 or Ripk1KDKI enteroids after DOX pretreatment and TNF stimulation. (E) Murine sepsis scores of five A20 Tg mice after TNF (1 μg) injection
without or with GSK′963 (50 mg/kg). Results are mean ± SD. P < 0.0001. (F) H&E or cC-3 staining of jejunal and colonic sections from A20 Tg mice injected with
TNF in the absence or presence of GSK′963. (Scale bars: 100 μm.)
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susceptibility to TNF-induced IEC death and microbial trans-
location (9). This effect, however, is dependent on necroptosis
and can be blocked by RIPK3 ablation (41). The TNF-induced
death of A20-expressing IECs, however, can only be prevented
by RIPK1 inhibitors.
Experimental Procedures
Mice. A20-Tg mice have been described (18). A20-Tg;Rag1+/− mice were used
for the in vivo experiments described herein. Ripk1D138N mice were obtained
from Vishva Dixit (Genentech) (42). Experimental animals were 8–12 wk of
age, all in the B6 genetic background, and maintained under specific-
pathogen-free (SPF) conditions at a University of California, San Diego
(UCSD) animal facility accredited by the American Association for Accredi-
tation of Laboratory Animal Care. All studies were conducted in accordance
with the GSK Policy on the Care, Welfare, and Treatment of Laboratory
Animals, and all animal protocols were approved by the UCSD Institutional
Review Board (IRB) following NIH guidelines. Mice were fed autoclaved
standard chow, and all of the different strains were cohoused to minimize
microbiome fluctuations.
Reagents. TNF (R&D Systems) was injected at 2 μg per mouse unless otherwise
indicated. In vitro, TNF was used at 40 ng/mL. DOX (1 μg/mL), zVAD-FMK
(50 μM), and BHA (10 μM) were purchased from Sigma. Necrostatin-1
(100 μM) was purchased from Calbiochem. The RIPK1 (963: 50 nM) and the
RIPK3 (843: 5 μM, 872: 5 μM) inhibitors were synthesized at GSK and purified
before use (23, 24). For in vivo studies, GSK′963 (50 mg/kg) was dissolved in
saline with 5% DMSO and 6% Cavitron, and injected i.p.
Human Samples. Archived colonic specimens for IHC analyses were obtained
from patients who underwent routine colonoscopy and were histologically
scored by an independent pathologist. Prospective colonic specimens for RNA
analysis were obtained from patients with CD and UC and from healthy
controls undergoing colonoscopy as part of routinemedical care at UCSD. The
participants had a diagnosis of CD or UC andwere at least 18 y of age. Healthy
controls had undergone routine colonoscopy and were not included if they
reported gastrointestinal symptoms. Patients’ clinical status was verified by
chart review of all medical records and laboratory and pathologic data, and
all specimens were deidentified before use. All participants provided written
informed consent, and studies were approved by the IRB at UCSD and the
VA San Diego Healthcare System.
RNA Sequencing and Bioinformatics. Total RNA was isolated from human
intestinal tissues and assessed for quality using an Agilent Bioanalyzer, and
samples with an RNA integrity number of 7 or greater were used to generate
cDNA libraries using Illumina’s TruSeq Stranded Total RNA Sample Prep Kit
starting with 100 ng of RNA. Libraries were sequenced on an Illumina
HiSeq2500 sequencer. Fastq files were aligned to the human transcriptome
of the Genome Reference Consortium GRCh.37/hg19, using the STAR aligner
(43). Transcript-level counts were calculated with the expectation maximi-
zation algorithm RSEM (44). Transcript-level summaries were processed into
gene-level summaries by combining all transcript counts from the same gene.
Gene counts from different samples were normalized and analyzed for dif-
ferential expression using DESeq (45). Since at least one of the samples does
not have biological replicates, we used an approach in which dispersion of
gene counts is estimated from all available samples as if they were replicates.
All presented measures of statistical significance should be viewed in this light.
Real-Time qPCR. Total RNAwas extractedwith TRIzol (Invitrogen) and reverse-
transcribed with random hexamers and a SuperScript II Kit (Invitrogen). qPCR
was performed with a SYBR Green PCR Master Mix Kit (Applied Biosystems).
Relative transcript amounts were compared with those of GAPDH mRNA andFig. 5. A20 enhances Ripoptosome activation and slows down deubiquiti-
nation of TNFR1-bound RIPK1. (A) FADD immunoprecipitates from B6 and
A20 Tg enteroids stimulated without (C) or with TNF (20 ng/mL) + zVAD
(10 μg/mL) (TZ) or TZ + Nec1 (50 μM) (TZN) in the absence or presence of cy-
cloheximide (CHX) were analyzed by IB as indicated. (B) TNFR1 immuno-
precipitates from B6 and A20 Tg enteroids stimulated with AviTag mTNF
(10 ng/mL) were analyzed by IB as indicated. (C) Lysates of B6 enteroids
transduced with the indicated iA20 constructs and treated with DOX and/or
TNF were analyzed by IB as indicated. (D) FADD immunoprecipitates of B6-
deficient or A20-deficient enteroids transduced with the indicated iA20
constructs and pretreated with DOX (as in C) before addition of TZ or TZN as
indicated. NS, nonspecific band.
Fig. 6. A20 dimerization is required for enhancement of RIPK1-dependent
apoptosis. (A) Lysates of B6- or A20-deficient enteroids transduced with the
indicated iA20 constructs that were DOX-pretreated and TNF-stimulated were
analyzed by IB as indicated. mTNF, mouse TNF. (B) IKK activity measured by
immune complex kinase assay in lysates of B6- and iA20HR-expressing A20-
deficient enteroids before and after TNF addition. (C) Lysates of B6- and
iA20HR-expressing enteroids treated as above were analyzed by IB for IκBα
expression. (D) FADD immunoprecipitates of B6- or A20-deficient enteroids
transduced with indicated iA20 constructs that were pretreated with DOX (as
in C) and then stimulated with TZ or TZN were analyzed by IB for the indicated
proteins (full figure in SI Appendix, Fig. S9). NS, nonspecific band.
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normalized to untreated samples by the delta-delta Ct (ΔΔCt) method. Pri-
mers are available upon request.
Histological and Immunohistochemical Analyses. Intestines were removed,
opened longitudinally, cleaned, processed as “Swiss rolls,” and fixed in 10%
phosphate-buffered formalin for 24 h. Formalin-fixed tissues were paraffin-
embedded, and 5-μm sections were prepared and stained with H&E. For IHC
analysis, mouse and human tissue sections were incubated overnight at 4 °C
with cC-3 antibodies (9661; Cell Signaling) at a 1:200 dilution. Antigen re-
trieval was with citrate buffer (pH 6.0) at 96 °C for 20 min. For double-
staining IHC, antigen retrieval was achieved by boiling the samples for
30 min in citrate buffer at pH 6.0. Tissue sections were incubated overnight
with an A20 primary antibody (ab111192) in PBS plus 3% BSA, and then
incubated with secondary alkaline phosphatase-linked antibody (1:200, AP-
9500) at room temperature for 1 h. After washing, slides were developed
using VectorRed (SK-5100; Vector Laboratories). Slides were further washed
and incubated overnight with the second primary antibody against cC-3
(9661; Cell Signaling). Samples were then incubated with the secondary
HRP-conjugated antibody (MP-7401; Vector Laboratories) and developed
with diaminobenzidine solution plus nickel (SK-4100; Vector Laboratories).
All sections were counterstained with hematoxylin and photographed using
an Axioplan 200 microscope with AxioVision Release 4.5 software (Zeiss).
Enteroid Isolation and Culture. Small intestinal organoids (enteroids) were
cultured as described (19). Briefly, crypts were collected from mouse small
intestine after a 30-min incubation in PBS (pH 7.4) containing 2 mM EDTA at
4 °C. Enteroids were plated in Matrigel (BD Bioscience) and maintained in
DMEM/F12 (Life Technologies) containing B27 and N2 supplements (Life
Technologies), 1.25 mM N-acetyl L-cysteine (Sigma), 100 ng/mL noggin
(GoldBio), 50 ng/mL mouse EGF (mEGF) (Biosource), and 10% Rspo1-Fc–
conditioned medium (the Rspo1-Fc–expressing cell line was a generous gift
from Calvin Kuo, Stanford University, Stanford, CA).
Immunoblotting and Immunoprecipitation. Whole-cell extracts were obtained
by lysing enteroids in ice-cold radioimmunoprecipitation assay lysis buffer
(Cell Signaling) containing 20 mM Tris·HCl (pH 7.5), 150 mM NaCl, 10 mM
EDTA, 1% Triton X-100, and 1% deoxycholate, supplemented with a pro-
tease and phosphatase inhibitor mixture (Roche). Proteins were separated
by SDS/PAGE and transferred to nitrocellulose membranes that were in-
cubated with antibodies against IκBα (Santa Cruz Biotechnology), RIPK1,
CYLD, cC-3, cC-8, A20, cIAP1, caspase-8, FADD (Cell Signaling), actin, and
tubulin (Sigma). For immunoprecipitation (IP) experiments, enteroids were
incubated with 100 μg/mL AviTag-mouse TNF (mTNF) for 1 h on ice and then
at 37 °C for 10, 30, and 60 min before collection. Cell extracts were immu-
noprecipitated with biotinylated magnetic beads (CST). In other experi-
ments, we used FADD antibody and Protein G Dynabeads (Life Technologies)
overnight at 4 °C. Immune complexes were washed with lysis buffer and
analyzed by IB. To isolate protein complexes by co-IP, the indicated anti-
bodies and cell lysates were incubated in 10 mM Tris (pH 7.4), 150 mM NaCl,
and 0.2% Nonident P-40.
Immunofluorescence. Enteroids in Matrigel were fixed with 4% para-
formaldehyde overnight at 4 °C. Fixed enteroids were blocked with PBS
containing 0.2% Triton X-100 and 1% BSA for 30 min and then immunos-
tained with primary antibodies overnight at 4 °C and with Alexa Fluor 594-
conjugated goat anti-rabbit IgG secondary antibody for 1 h at room tem-
perature. Immunostained enteroids were gently mounted on glass slides and
imaged under a Leica confocal microscope.
Constructs and Lentivirus Transduction of Enteroids. Inducible-A20 lentiviral
expression constructs were made by subcloning PCR-amplified attB-flanked
full-length A20 (14) and the different A20 mutants (16). cDNAs were PCR-
amplified and cloned into pINDUCER20 (46) using the Gateway Clonase II
system (Life Technologies). All constructs were verified by sequencing.
Lentiviral constructs were transfected along with pMD2.G (Plasmid 12259;
Addgene) and psPAX2 (Plasmid 12260; Addgene) into 293T cells to produce
viral particles used to infect enteroids as described (47). Briefly, 2 d before
virus infection, enteroids were supplemented with 50% Wnt3a conditioned
medium (the Wnt3a-expressing cell line was a generous gift from Karl Wil-
lert, UCSD) and 10 mM nicotinamide. Single cells were obtained by digesting
the enteroids with TrypLE (Life Technologies) for 5 min at 37 °C. Cells were
mixed with high-titer lentivirus plus polybrene (8 μg/mL; Santa Cruz Bio-
technology) and Y-27632 (10 μM; Sigma) in a 48-well culture plate and
centrifuged at 600 × g at 32 °C for 60 min, followed by a 5-h incubation at
37 °C. Cells were then plated in Matrigel and cultured in media with 50%
Wnt3a, nicotinamide, and Y-27632 for 2 d, followed by selection with pu-
romycin (1 μg/mL) or G418 (800 ng/mL) in regular media for 1 wk.
Statistical Analysis. Statistical analysis was performed with Prism software
(version 5; GraphPad). Results are expressed as mean ± SEM if not otherwise
indicated. Normality of the variables was assessed using the Kolmogorov–
Smirnov and D’Agostino–Pearson normality tests. For comparison between
two groups, the Student’s two-tailed t test or nonparametric Mann–Whitney
test was applied, depending on the normality of the distribution of the var-
iables. We compared three or more groups with analysis of variance; either
Dunnett’s post hoc test or the Bonferroni test was chosen, depending on the
homogeneity of variances. For correlation studies, the Pearson or Spearman
test was applied depending on the normality of distribution of the variables.
Results were considered significant if the two-sided P value was less than 0.05.
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